T1	Pharmacological_substance 65 75	rifampicin
N1000 	Reference T1 MeSH:D012293	rifampicin
T2	Pharmacological_substance 99 117	opinavir/ritonavir
T4	Pharmacological_substance 189 199	rifampicin
N1001 	Reference T4 MeSH:D012293	rifampicin
T5	Pharmacological_substance 222 241	lopinavir/ritonavir
T7	Pharmacological_substance 293 302	lopinavir
N1002 	Reference T7 MeSH:D061466	lopinavir
T8	Pharmacological_substance 351 361	rifampicin
N1003 	Reference T8 MeSH:D012293	rifampicin
T9	Pharmacological_substance 387 406	lopinavir/ritonavir
T12	Pharmacological_substance 483 493	rifampicin
N1004 	Reference T12 MeSH:D012293	rifampicin
T13	Pharmacological_substance 574 593	lopinavir/ritonavir
T17	Pharmacological_substance 680 690	rifampicin
N1005 	Reference T17 MeSH:D012293	rifampicin
T18	Pharmacological_substance 933 943	rifampicin
N1006 	Reference T18 MeSH:D012293	rifampicin
T19	Pharmacological_substance 969 988	lopinavir/ritonavir
T21	Disorder 1026 1032	nausea
N1 	Reference T21 UMLS:C0027497	nausea
T22	Disorder 1037 1045	vomiting
N2 	Reference T22 UMLS:C0042963	vomiting
T23	Disorder 1056 1062	nausea
N3 	Reference T23 UMLS:C0027497	nausea
T24	Disorder 1082 1090	vomiting
N4 	Reference T24 UMLS:C0042963	vomiting
T30	Pharmacological_substance 1526 1545	lopinavir/ritonavir
T32	Pharmacological_substance 1572 1582	rifampicin
N1007 	Reference T32 MeSH:D012293	rifampicin
T33	Pharmacological_substance 1714 1724	rifampicin
N1008 	Reference T33 MeSH:D012293	rifampicin
T34	Pharmacological_substance 1729 1747	lopinavir/ritonavi
T11	Subject 427 448	40 healthy volunteers
T15	Subject 536 546	volunteers
T16	Subject 36 54	healthy volunteers
T36	Subject 148 166	healthy volunteers
T37	Subject 828 845	Eleven volunteers
T38	Subject 990 1006	eight volunteers
T39	Subject 1206 1220	all volunteers
T40	Combination 1558 1566	combined
T41	Subject 1644 1662	healthy volunteers
T42	Combination 1753 1761	combined
T44	Disorder 18 32	adverse events
T46	Combination 76 79	and
T3	Subject 1047 1050	one
T6	Subject 1073 1076	one
T27	Combination 335 343	combined
T28	Combination 200 203	and
T35	Disorder 1467 1481	adverse events
T54	Combination 661 669	addition
T26	Speculation_cue 1699 1708	monitored
